----

----

| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------------------------------------------------------------------------------------|

|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|------------------------------------------------------------------------------------------|

| Delaware                                                      |   | 93-0987903                          |
|---------------------------------------------------------------|--------|-------------------------------------|
| (State or other jurisdiction ofincorporation or organization) |   | (I.R.S. EmployerIdentification No.) |
|                                                          |   |
| 11588 Sorrento Valley Rd., Suite 20, San Diego, CA            |   | 92121                               |
| (Address of principal executive offices)                      |   | (Zip Code)                          |

| Title of Each Class |   | Name of Each Exchange on Which Registered |
|---------------------|--------|-------------------------------------------|
| None                |   |                                      |

----

| Large accelerated filer |   |  ̈ |    | Accelerated filer                   |   |  ̈ |
|-----------------------------------|--------|--------|--------------|-------------------------------------|--------|--------|
|                              |   |   |         |
| Non-accelerated filer        |   |  ̈ |    | Smaller reporting company |   | x      |

----

----

----

| Name                       |   | Position                                                                                      |
|---------------------------------|--------|----------------------------------------------------------------------------------------------------|
| J. David Hansen                 |   | Chairman of the Board of Directors, President and Chief Executive Officer |
|                            |   |
| Kenneth M. Cohen                |   | Director (1)(2)(3)                                                                                 |
|                            |   |
| Robert E. Hoffman               |   | Director (1)(2)(3)                                                                                 |
|                            |   |
| Philip O. Livingston, M.D.      |   | Director, Chief Science Officer                                                                    |
|                            |   |
| Paul V. Maier                   |   | Director (1)(3)                                                                                    |
|                            |   |
| Jeffrey V. Ravetch, M.D., Ph.D. |   | Director (2)                                                                                       |
|                            |   |
| Thomas C. Varvaro               |   | Director (1)(2)(3)                                                                                 |
|                            |   |                                                                                               |
|                            |   |

|   | (1) | Member of our audit committee |
|--------|-----|-------------------------------|

|   | (2) | Member of our compensation committee |
|--------|-----|--------------------------------------|

|   | (3) | Member of our nominating and governance committee |
|--------|-----|---------------------------------------------------|

----

----

----

| INDEPENDENCEOFTHE BOARDOF DIRECTORSANDITS COMMITTEES |
|------------------------------------------------------|

----

----

----

|  Name                |   |  Position                                                                                     |
|---------------------------|--------|----------------------------------------------------------------------------------------------------|
| J. David Hansen.          |   | Chairman of the Board of Directors, President and Chief Executive Officer |
|                      |   |
| Gregory P. Hanson, CMA    |   | Chief Financial Officer                                                                            |
|                      |   |
| Wolfgang W. Scholz, Ph.D. |   | Vice President of Antibody Discovery                                                               |
|                      |   |
| Paul W. Maffuid, Ph.D.    |   | Vice President of Pharmaceutical Development and Operations                                        |

----

| Name and Principal Position                                  | Year | Salary ($)                                                                                              | Bonus ($) | Option Awards ($)(5)                                                                                          | All Other Compensation ($) | Total ($)(1)                                                                                                                                        |
|--------------------------------------------------------------|------|--------------------------------------------------------------------------------------------------------------|----------------|---------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| J. David Hansen                                              | 2014 |               322,176                  |  -0-      |  -0-                                                                                                     | 25,142                     |               347,318                                                         |
| President, Chief Executive Officer and Chairman(2)           | 2013 | 313,892                                                                                                      | 32,318         | 296,226                                                                                                       | 25,719                     |              668,155                                                               |
| Michael M. Wick, M.D., Ph.D.                                 | 2014 |               391,630                  |  -0-      | -0-                                                                                                           |  -0-                  |               391,630                                                         |
| Former President, Chief Executive Officer and Chairman(2)(3) | 2013 |  344,000 (3)                                                                                            |  -0-      |  -0-                                                                                                     |  -0-                  |               344,000                                                         |
| Gregory P. Hanson                                            | 2014 |               190,122                  |  -0-      |               56,331                    |  2,664                |               249,117                                                         |
| Chief Financial Officer(2)                                   | 2013 |  -0-                                                                                                    |  -0-      |  -0-                                                                                                     |  -0-                  |                         -0- |
| Wolfgang W. Scholz, Ph.D.                                    | 2014 |               208,630                  | -0-            | -0-                                                                                                           |  14,609               |               223,239                                                         |
| Vice President, Antibody Discovery                           | 2013 |  212,702                                                                                                |  18,891   |                  197,484 | 14,956                |                  444,033                                       |
| Paul W. Maffuid                                              | 2014 |                  90,961 |  -0-      |               90,676                    | 9,930                      |               191,567                                                         |
| Vice President, Pharmaceutical Development and Operations(4) | 2013 |  -0-                                                                                                    |  -0-      |  -0-                                                                                                     |  -0-                  |  -0-                                                                                                                                           |

| (1) | This table includes compensation from the Company, and from MabVax Therapeutics, Inc., its predecessor, prior to the July 2014 merger. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Mr. Wick resigned his executive positions on July 7, 2014 in connection with the Merger. Mr. Hansen and Mr. Hanson were appointed to their positions in connection with the Merger on the same date. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Dr. Wick was not compensated for his role as a director in 2014. The amount shown reflects salary earned as an employee only. |
|-----|------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Dr. Maffuid was appointed to his position in July 2014. |
|-----|--------------------------------------------------------------|

| (5) | The amounts in this column represent the aggregate full grant date fair values of stock options granted, computed in accordance with Accounting Standards Codification 718, or ASC 718, “Compensation—Stock Compensation” using the Black-Scholes option valuation model. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Name and Principal Position                               |   | Option Grant Date |   |   | Number of Securities Underlying Unexercised Options Exercisable (#) |   |   | Number of Securities Underlying Unexercised Options Un-exercisable (#) |   |   | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |   |   | Option Exercise Price per Share ($) |   |   | Option Expiration Date |   |
|-----------------------------------------------------------|--------|-------------------|--------|--------|---------------------------------------------------------------------|--------|--------|------------------------------------------------------------------------|--------|--------|------------------------------------------------------------------------------------------------|--------|--------|-------------------------------------|--------|--------|------------------------|--------|
| Michael M. Wick                                           |   |              |   |   |                                                                |   |   |                                                                   |   |   |                                                                                           |   |   |                                |   |   |                   |   |
| Former President, Chief Executive Officer and Chairman(1) |   |              | --     |   |                                                                |   | -0-    |                                                                   |   |   | -0-                                                                                            |   |   |                                | -0-    |   |                   |   | -0- |   |   |   | -0- |   |
| J. David Hansen                                           |   | 2/1/2010          |   |   |                                                                | 12,506 |   |                                                                   |   | -0-    |                                                                                           |   |   | -0-                                 |   |   |                   | 0.72   |   |   | 2/1/2020 |   |
| President, Chief Executive Officer and Chairman(1)        |   | 2/28/2013         |   |   |                                                                | 11,464 |   |                                                                   |   | 13,548 |                                                                                           |   |   | -0-                                 |   |   |                   | 1.44   |   |   | 2/28/2023 |   |
| Gregory P. Hanson                                         |   |              |   |   |                                                                |   |   |                                                                   |   |   |                                                                                           |   |   |                                |   |   |                   |   |   |   |   |   |   |   |
| Chief Financial Officer(1)                                |   | 3/13/2014         |   |   |                                                                | 8,511  |   |                                                                   |   | 10,943 |                                                                                           |   |   | -0-                                 |   |   |                   | 8.10   |   |   | 3/13/2024 |   |
| Wolfgang W. Scholz, Ph.D.                                 |   | 2/1/2010          |   |   |                                                                | 6,948  |   |                                                                   |   | -0-    |                                                                                           |   |   | -0-                                 |   |   |                   | 0.72   |   |   | 2/1/2020 |   |
| Vice President, Antibody Discovery                        |   | 2/28/2013         |   |   |                                                                | 7,643  |   |                                                                   |   | 9,032  |                                                                                           |   |   | -0-                                 |   |   |                   | 1.44   |   |   | 2/28/2023 |   |
| Paul W. Maffuid                                           |   |              |   |   |                                                                |   |   |                                                                   |   |   |                                                                                           |   |   |                                |   |   |                   |   |   |   |   |   |   |   |
| Vice President, Pharmaceutical Development and Operations |   | 9/8/2014          |   |   |                                                                | -0-    |   |                                                                   |   | 13,895 |                                                                                           |   |   | -0-                                 |   |   |                   | 8.48   |   |   | 9/8/2024 |   |

| (1) | Mr. Wick resigned his positions on July 7, 2014 in connection with the Merger. Mr. Hansen and Mr. Hanson were appointed to their positions in connection with the Merger on the same date. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Participants                      |    | Severance and ReleasePayment Amount |    |
|-----------------------------------|--------------|----------------------------------------------------|---------|
| Michael M. Wick, M.D., Ph.D. |    | $                                                  | 172,000 |    |
| Gail L. Brown, M.D.               |    | $                                                  | 136,000 |    |
| William P. Kaplan, Esq.           |    | $                                                  | 118,000 |    |
| Steven R. Schow, Ph.D.            |    | $                                                  | 120,000 |    |
| Wendy K. Wee                      |    | $                                                  | 118,000 |    |

----

----

| Name of Director               |   | Fees Earned or Paid in Cash ($) |   |   | Option Awards ($) (1) |   |   | Total ($) |   |
|--------------------------------|--------|--------------------------------------|--------|--------|----------------------------|--------|--------|-----------|--------|
| Edward W. Cantrall, Ph.D. (4)  |   | $                                    | 24,000 |   |                       |   | --     |      |   | $ | 24,000 |   |
| Steven R. Goldring, M.D. (4)   |   | $                                    | 24,000 |   |                       |   | --     |      |   | $ | 24,000 |   |
| Richard B. Newman, Esq. (4)    |   | $                                    | 24,000 |   |                       |   | --     |      |   | $ | 24,000 |   |
| Philip O. Livingston, M.D. (2) |   |                                 | --     |   |                       |   | --     |      |   |   | -- |   |
| Robert E. Hoffman              |   | $                                    | 8,250  |   |                       | $      | 62,953 |      |   | $ | 71,203 |   |
| Jeffrey Ravetch, M.D.          |   | $                                    | 14,500 |   |                       | $      | 28,971 |      |   | $ | 43,471 |   |
| Paul V. Maier                  |   | $                                    | 11,750 |   |                       | $      | 75,020 |      |   | $ | 86,770 |   |
| Kenneth M. Cohen               |   | $                                    | 13,190 | (3)    |                       | $      | 75,020 |      |   | $ | 102,710 |   |

| (1) | The amounts in this column represent the aggregate full grant date fair values of stock options granted to each of the non-employee directors computed in accordance with Accounting Standards Codification 718, or ASC 718, “Compensation—Stock Compensation,” excluding the effect of estimated forfeitures. For additional information on the valuation assumptions, refer to “Stock-based Compensation under ASC 718” and “Valuation Assumptions” under the “Notes to the Financial Statements” in MabVax Holdings’ Form 10-K for the year ended December 31, 2014, as filed with the SEC. The amounts reported for these options may not represent the actual economic values that MabVax Holdings’ non-employee directors will realize from these options, as the actual value realized will depend on MabVax Holdings’ performance, stock price and their continued services. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Dr. Livingston does not receive any compensation as a director.  Dr. Livingston’s employee compensation in 2014 consisted of $60,000 in cash compensation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| (3) | This amount does not include $14,500 paid to Mr. Cohen as a consultant, prior to his election as a director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| (4) | Director prior to the Merger.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

----

| Name of Director              |   | Option Grant Date |   |   | Exercise Price Per Share ($) |   |   | Full Grant Date Fair Value ($) |   |   | Total Shares Subject to Outstanding Options at 12/31/14 |   |
|-------------------------------|--------|-------------------|--------|--------|------------------------------|--------|--------|--------------------------------|--------|--------|---------------------------------------------------------|--------|
| Edward W. Cantrall, Ph.D. (1) |   |              | --     |   |                         |   | --     |                           |   |   | --                                                      |   |   |   | -- |   |
| Steven R. Goldring, M.D. (1)  |   |              | --     |   |                         |   | --     |                           |   |   | --                                                      |   |   |   | -- |   |
| Richard B. Newman, Esq. (1)   |   |              | --     |   |                         |   | --     |                           |   |   | --                                                      |   |   |   | -- |   |
| Philip O. Livingston, M.D.    |   |              | --     |   |                         |   | --     |                           |   |   | --                                                      |   |   |   | -- |   |
| Robert E. Hoffman             |   | 9/8/2014          |   |   | $                            | 8.48   |   |                           | $      | 62,953 |                                                    |   |   | 11,116 |   |
| Jeffrey Ravetch, M.D.         |   | 3/13/2014         |   |   | $                            | 8.10   |   |                           | $      | 28,971 |                                                    |   |   | 11,116 |   |
| Paul V. Maier                 |   | 6/30/2014         |   |   | $                            | 9.14   |   |                           | $      | 75,020 |                                                    |   |   | 11,116 |   |
| Kenneth M. Cohen              |   | 6/30/2014         |   |   | $                            | 9.14   |   |                           | $      | 75,020 |                                                    |   |   | 11,116 |   |

| (1) | Director prior to the Merger. |
|-----|-------------------------------|

| •   | Each Non-employee Board member shall receive a cash retainer of $24,000 per year. Chairmen of each committee shall receive an additional cash retainer as follows: (i) $12,000 for the Chairman of the Audit Committee; (ii) $8,000 for the Chairman of the Compensation Committee; and (iii) $5,000 for the Chairman of the Nominating Committee. All such retainers will be paid on a quarterly basis; |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| •   | Each current Board member received a one-time grant, and each new member going forward shall receive an initial one time grant of: 68,500 shares of Common Stock, half of which shall be comprised of restricted stock units and half of which shall be comprised of stock option with three year annual vesting; and |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| •   | Each Non-employee Board member will also receive an automatic annual grant of 35,000 stock options, with one year vesting. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------|

----

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. |
|---------------|-------------------------------------------------------------------------------------------------|

|                                                       |    | (a)                                                                                                                   |    |    | (b)                                                                                           |   |    | (c)                                                                                                                                                                                  |         |
|------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------------------------------|---------|--------------|-----------------------------------------------------------------------------------------------|--------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
|  Plan Category                                        |    | Number of Securitiesto be Issued UponExercise ofOutstanding Options,Warrants and Rights |    |    | Weighted-averageExercise  Price ofOutstanding Options,Warrants and Rights |   |    | Number of  SecuritiesRemaining Available forFuture Issuance UnderEquity Compensation  Plans(Excluding SecuritiesReflected in Column (a) |         |
| Equity compensation plans approved by security holders     |    |                                                                                                                  | 242,893 |         |                                                                                          | $      | 3.92         |                                                                                                                                                                                 |         |   | 326,431 |   |
| Equity compensation plans not approved by security holders |    |                                                                                                                  | — |    |                                                                                     |   | N/A          |                                                                                                                                                                            |    |   | — |    |
| Total                                                      |    |                                                                                                                  | 242,893 |         |                                                                                          |   |         |                                                                                                                                                                                 |         |   | 326,431 |   |

|   | • |   | each person known by us to beneficially own more than 5% of the Company’s common stock; |
|--------|---------|--------|-----------------------------------------------------------------------------------------------|

|   | • |   | each of our directors; |
|--------|---------|--------|------------------------|

|   | • |   | each of our executive officers; and |
|--------|---------|--------|-------------------------------------|

|   | • |   | all of our directors and executive officers as a group. |
|--------|---------|--------|---------------------------------------------------------|

|  Name and Address of Beneficial Owner                   |    | Number of Shares ofCommon Stock |           |    | Percentage ofCommon Stock |   |
|--------------------------------------------------------------|--------------|------------------------------------------------|----------------|--------------|-------------------------------------|--------|
| 5% Stockholders                                              |    |                                           |           |         |                           |   |   |   |
| RTP Venture Fund (1)                                         |         |                                           | 1,447,037      |         |                                |   | 6.45 | % |
| Frost Gamma Investment Trust (2)                             |    |                                           | 1,333,333      |    |                           |   | 5.95 | %  |
| Pinnacle Family Office Investments                           |         |                                           | 1,333,333      |         |                                |   | 5.95 | %  |
| Andy Sassine                                                 |         |                                           | 1,333,333      |         |                                |   | 5.95 | %  |
| Alpha Capital Anstalt                                        |         |                                           | 1,332,313      |         |                                |   | 5.94 | % |
| Total 5% stockholders                                        |    |                                           | 6,779,349      |    |                           |   | 30.24 | %  |
|                                                         |    |                                           |           |         |                           |   |   |   |
| Directors and Executive Officers                             |    |                                           |           |         |                           |   |   |   |
| Philip O. Livingston, M.D. (1)                               |    |                                           | 1,447,037      |    |                           |   | 6.45 | % |
| Jeffrey Ravetch, M.D., Ph.D. (5)                             |    |                                           | 142,616        |         |                                |   | * |   |
| J. David Hansen (3)                                          |    |                                           |   93,271  |    |                           |   | * |    |
| Wolfgang W. Scholz, Ph.D. (6)                                |    |                                           |  66,350   |    |                           |   | * |    |
| Robert E. Hoffman (4)                                        |         |                                           |  21,116   |         |                                |   | * |   |
| Kenneth M. Cohen (8)                                         |         |                                           | 17,616         |         |                                |   | * |   |
| Paul V. Maier (7)                                            |    |                                           | 11,116         |    |                           |   | * |   |
| Gregory P. Hanson                                            |    |                                           | 9,079          |    |                           |   | * |    |
| Paul W. Maffuid, Ph.D.                                       |    |                                           | 5,000          |    |                           |   | * |    |
| Thomas C. Varvaro                                            |    |                                           | —        |    |                           |   | * |    |
|                                                         |         |                                           |   sd |         |                                |   |   |   |
| All executive officers and directors as a group (11 persons) |    |                                           | 1,813,201      |    |                           |   | 8.05 | %  |

|  * | Less than 1%. |
|---------|---------------|

| (1) | Consists of (i) 1,307,396 shares held by RTP Venture Fund, (ii) 110,147 shares held by Philip O. Livingston, (iii) 12,734 shares held by the Joan L. Tweedy 2011 Revocable Trust, or the Tweedy Trust, and (iv) 16,760 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015) held by Philip O. Livingston. Voting and dispositive decisions of RTP Venture Fund, LLC are made by Philip Livingston, and Philip O. Livingston is a trustee of the Tweedy Trust. The address for RTP Venture Fund, LLC is 156 E. 79th Street, Apt. 6C, New York, NY 10075. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (2) | Does not include warrants to purchase 666,667 shares of the Company’s common stock owned by Phillip Frost, M.D., which contains a 4.99% beneficial ownership blocker. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Includes 26,573 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015). |
|-----|---------------------------------------------------------------------------------------------------------|

| (4) | Includes 11,116 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015). |
|-----|---------------------------------------------------------------------------------------------------------|

| (5) | Includes 11,116 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015). |
|-----|---------------------------------------------------------------------------------------------------------|

| (6) | Includes 16,326 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015). |
|-----|---------------------------------------------------------------------------------------------------------|

| (7) | Includes 11,116 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015). |
|-----|---------------------------------------------------------------------------------------------------------|

| (8) | Includes 11,116 shares subject to options exercisable within 60 days of April 24, 2015 (June 24, 2015). |
|-----|---------------------------------------------------------------------------------------------------------|

| Item 13. | Certain Relationships and Related Transactions, and Director Independence. |
|---------------|----------------------------------------------------------------------------|

| Item 14. | Principal Accounting Fees and Services |
|---------------|----------------------------------------|

|                  |   | December 31,    |    |
|-----------------------|--------|-----------------|---------|
|                  |   | 2014            |    |   | 2013 |   |
|                  |   | CohnReznick LLP |    |   | Ernst & Young LLP |   |   | Burr Pilger Mayer, Inc. |   |
| Audit Fees            |   | $               | 318,925 |  (1) |   | $ | 105,450 |   |   | $ | 87,650 |   |
| Audit-Related Fees(2) |   |            | -       |   |   |   | - |   |   |   | - |   |
| Tax Fees(3)           |   |            | -       |   |   |   | - |   |   |   | - |   |
| All Other Fees        |   |            | -       |   |   |   | - |   |   |   | - |   |
| Total Fees(4)         |   | $               | 318,925 |   |   | $ | 105,450 |   |   | $ | 87,650 |   |

| (1) |   | This amount includes $200,889 for audit and review services in connection with the Merger in 2014 and $118,036 for audit services for 2012 and 2013. |
|-----|--------|------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) |   | There were no audit-related fees billed for the fiscal years ended December 31, 2014 and 2013. |
|-----|--------|-----------------------------------------------------------------------------------------------------|

| (3) |   | Tax Fees would be for services in connection with tax compliance, tax planning and tax advice. We incurred no such fees in the fiscal years ended December 31, 2014 and 2013. |
|-----|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) |   | There were no other fees for services by our independent registered public accounting firms for the fiscal years ended December 31, 2014 and 2013. |
|-----|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Item 15. | Exhibits and Financial Statement Schedules. |
|---------------|---------------------------------------------|

|  ExhibitNo. |    |  Description                                                                                                                                                                                                                                                                                                                                                            |    |  Form |    | FilingDate/PeriodEnd |    |  ExhibitNumber |
|------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------|----------------------|--------------|---------------------|
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 2.1              |    | Agreement and Plan of Merger and Reorganization, dated May 12, 2014, between the Company, Tacoma Acquisition Corp., Inc. and MabVax Therapeutics, Inc.                                                                                                                                                                                                                       |    | 8-K        |    | 5/12/2014            |    | 2.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 2.2              |    | Amendment No.1, dated as of June 30, 2014, by and between the Company and MabVax Therapeutics, Inc.                                                                                                                                                                                                                                                                          |    | 8-K        |    | 7/1/2014             |    | 2.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 2.3              |    | Amendment No.2 to the Agreement and Plan of Merger, dated July 7, 2014, by and among the Company, Tacoma Acquisition Corp. and MabVax Therapeutics, Inc.                                                                                                                                                                                                                     |    | 8-K        |    | 7/9/2014             |    | 2.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.1              |    | Certificate of Designations, Preferences and Rights of Series A-1 Convertible Preferred Stock                                                                                                                                                                                                                                                                                |    | 8-K        |    | 7/9/2014             |    | 3.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.2              |    | Amended and Restated Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock                                                                                                                                                                                                                                                             |    | 8-K        |    | 7/9/2014             |    | 3.2                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.3              |    | Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock                                                                                                                                                                                                                                                                                  |    | 8-K        |    | 9/3/2014             |    | 3.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.4              |    | Amended and Restated Certificate of Incorporation                                                                                                                                                                                                                                                                                                                            |    | 8-K        |    | 9/9/2014             |    | 3.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.5              |    | Certificate of Amendment of Amended and Restated Certificate of Incorporation                                                                                                                                                                                                                                                                                                |    | 8-K        |    | 9/9/2014             |    | 3.2                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.6              |    | Amended and Restated Bylaws                                                                                                                                                                                                                                                                                                                                                  |    | 8-K        |    | 12/14/2007           |    | 3.2                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.7              |    | Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock                                                                                                                                                                                                                                                                                  |    | 8-K        |    | 3/26/2015            |    | 3.1                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 3.8              |    | Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock                                                                                                                                                                                                                                                                                  |    | 10-K       |    | 3/31/2015            |    | 3.8                 |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 4.1              |    | Securities Purchase Agreement, dated May 12, 2014, between the Company and the investors identified on the Schedule of Buyers therein and the Form of Registration Rights Agreement, attached thereto as Exhibit C                                                                                                                                                 |    | 8-K        |    | 5/12/2014            |    | 10.1                |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 4.2              |    | Securities Purchase Agreement, dated as of February 12, 2014, between MabVax Therapeutics, Inc. and the purchasers set forth on the signature pages thereto including that certain Amendment No. 1 to Securities Purchase Agreement, dated as of May 12, 2014, between MabVax Therapeutics, Inc. and the persons and entities identified on the signature pages thereto |    | 8-K        |    | 5/12/2014            |    | 10.3                |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 4.3              |    | Registration Rights Agreement, dated as of February 12, 2014, between MabVax Therapeutics, Inc. and the persons and entities identified on the signature pages thereto                                                                                                                                                                                                       |    | 8-K        |    | 5/12/2014            |    | 10.2                |
|             |         |                                                                                                                                                                                                                                                                                                                                                                         |         |       |
| 4.4              |    | Omnibus Amendment and Stockholder Consent, dated July 7, 2014, by and among the Company and the Purchasers                                                                                                                                                                                                                                                              |    | 8-K        |    | 7/9/2014             |    | 10.1                |

| 4.5    |    | Form of Parent Common Stock Warrant                                                                                                    |    | 8-K    |    | 7/9/2014  |    | 4.1  |
|--------|--------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|--------------|-----------|--------------|------|
|   |         |                                                                                                                                   |         |   |
| 4.6    |    | Form of Warrant to Purchase Common Stock                                                                                               |    | 8-K    |    | 7/9/2014  |    | 4.2  |
|   |         |                                                                                                                                   |         |   |
| 4.7    |    | Form of Exchange Agreement                                                                                                             |    | 8-K    |    | 9/3/2014  |    | 10.1 |
|   |         |                                                                                                                                   |         |   |
| 4.8    |    | Form of Waiver Letter                                                                                                                  |    | 8-K    |    | 9/3/2014  |    | 10.2 |
|   |         |                                                                                                                                   |         |   |
| 4.9    |    | Form of Common Stock Certificate                                                                                                       |    | S-1    |    | 9/29/2014 |    | 4.1  |
|   |         |                                                                                                                                   |         |   |
| 4.10   |    | Form of Waiver Extension Letter                                                                                                        |    | 8-K    |    | 9/30/2014 |    | 10.1 |
|   |         |                                                                                                                                   |         |   |
| 4.11   |    | Form of Subscription Agreement, dated March 31, 2015, between the Company and the subscribers set forth on the signature pages thereto |    | 10-K   |    | 3/31/2015 |    | 4.11 |

----

| 4.12   |    | Form of Common Stock Purchase Warrant                                                                                                                   |    | 10-K   |    | 3/31/2015  |    | 4.12  |
|--------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|--------------|------------|--------------|-------|
|   |         |                                                                                                                                                    |         |   |
| 4.13   |    | Form of Registration Rights Agreement, dated March 31, 2015, between the Company and the persons and entities identified on the signature pages thereto |    | 10-K   |    | 3/31/2015  |    | 4.13  |
|   |         |                                                                                                                                                    |         |   |
| 10.1   |    | Separation Agreement and Release, dated May 12, 2014, between Michael M. Wick and the Company                                                      |    | 8-K    |    | 5/12/2014  |    | 10.4  |
|   |         |                                                                                                                                                    |         |   |
| 10.2   |    | Separation Agreement and Release, dated May 12, 2014, between William P. Kaplan and the Company                                                    |    | 8-K    |    | 5/12/2014  |    | 10.5  |
|   |         |                                                                                                                                                    |         |   |
| 10.3   |    | Separation Agreement and Release, dated May 12, 2014, between Steven R. Schow and the Company                                                      |    | 8-K    |    | 5/12/2014  |    | 10.6  |
|   |         |                                                                                                                                                    |         |   |
| 10.4   |    | Separation Agreement and Release, dated May 12, 2014, between Wendy K. Wee and the Company                                                         |    | 8-K    |    | 5/12/2014  |    | 10.7  |
|   |         |                                                                                                                                                    |         |   |
| 10.5   |    | Michael Wick Resignation Letter, dated July 7, 2014                                                                                                     |    | 8-K    |    | 7/9/2014   |    | 99.1  |
|   |         |                                                                                                                                                    |         |   |
| 10.6   |    | Edward W. Cantrall Resignation Letter, dated July 7, 2014                                                                                          |    | 8-K    |    | 7/9/2014   |    | 99.2  |
|   |         |                                                                                                                                                    |         |   |
| 10.7   |    | Steven R. Goldring Resignation Letter, dated July 7, 2014                                                                                          |    | 8-K    |    | 7/9/2014   |    | 99.3  |
|   |         |                                                                                                                                                    |         |   |
| 10.9   |    | Richard B. Newman Resignation Letter, dated July 7, 2014                                                                                           |    | 8-K    |    | 7/9/2014   |    | 99.4  |
|   |         |                                                                                                                                                    |         |   |
| 10.10  |    | Employment Agreement, dated July 8, 2014, by and between MabVax Therapeutics, Inc. and J. David Hansen                                             |    | 10-Q   |    | 8/8/2014   |    | 10.9  |
|   |         |                                                                                                                                                    |         |   |
| 10.11  |    | Employment Agreement, dated July 8, 2014, by and between MabVax Therapeutics, Inc. and Gregory P. Hanson                                                |    | 10-Q   |    | 8/8/2014   |    | 10.10 |
|   |         |                                                                                                                                                    |         |   |
| 10.12  |    | Employment Agreement, dated July 8, 2014, by and between MabVax Therapeutics, Inc. and Wolfgang W. Scholz, Ph.D.                                        |    | 10-Q   |    | 8/8/2014   |    | 10.11 |
|   |         |                                                                                                                                                    |         |   |
| 10.13  |    | Securities Purchase Agreement, dated July 8, 2014, by and between MabVax Therapeutics, Inc. and certain institutional investors set forth therein       |    | 10-Q   |    | 8/8/2014   |    | 10.12 |
|   |         |                                                                                                                                                    |         |   |
| 10.14  |    | Form of Indemnification Agreement                                                                                                                       |    | 8-K    |    | 9/9/2014   |    | 10.1  |
|   |         |                                                                                                                                                    |         |   |
| 10.15  |    | Second Amended and Restated MabVax Therapeutics Holdings, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan                             |    | 10-K   |    | 3/31/2015  |    | 10.15 |
|   |         |                                                                                                                                                    |         |   |
| 10.16  |    | Non-Employee Director Compensation Policy                                                                                                               |    | S-1    |    | 9/29/2014  |    | 10.22 |
|   |         |                                                                                                                                                    |         |   |
| 10.17  |    | Standard Industrial Net Lease, dated as of May 23, 2008, by and between MabVax Therapeutics, Inc. and Sorrento Square                              |    | S-1    |    | 9/29/2014  |    | 10.23 |
|   |         |                                                                                                                                                    |         |   |
| 10.18  |    | First Amendment to that Standard Industrial Net Lease, dated May 6, 2010, by and between MabVax Therapeutics, Inc. and Sorrento Square                  |    | S-1    |    | 9/29/2014  |    | 10.24 |
|   |         |                                                                                                                                                    |         |   |
| 10.19  |    | Second Amendment to that Standard Industrial Net Lease, dated August 1, 2012, by and between the Company and Sorrento Square                            |    | S-1    |    | 9/29/2014  |    | 10.25 |
|   |         |                                                                                                                                                    |         |   |
| 10.20  |    | Employment Agreement, dated July 21, 2014, 2014, by and between MabVax Therapeutics, Inc. and Paul Maffuid, Ph.D.                                  |    | S-1    |    | 9/29/2014  |    | 10.31 |
|   |         |                                                                                                                                                    |         |   |
| 10.21  |    | Development and Manufacturing Services Agreement, dated April 15, 2014, by and between MabVax Therapeutics, Inc. and Gallus BioPharmaceuticals NJ, LLC  |    | S-1/A  |    | 10/14/2014 |    | 10.26 |

| 10.22  |    | Exclusive License Agreement for “Polyvalent Conjugate Vaccines for Cancer” (SK#14491), dated as of June 30, 2008, by and between MabVax Therapeutics, Inc. and Sloan-Kettering Institute for Cancer Research |    | S-1/A  |    | 10/14/2014 |    | 10.27 |
|--------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|--------------|------------|--------------|-------|
|   |         |                                                                                                                                                                                                                          |         |   |
| 10.23  |    | Research and License Agreement, dated as of April 7, 2008, by and between MabVax Therapeutics, Inc. and Sloan-Kettering Institute for Cancer Research                                                                    |    | S-1/A  |    | 10/14/2014 |    | 10.28 |
|   |         |                                                                                                                                                                                                                          |         |   |
| 10.24  |    | Exclusive License to Unimolecular Antibodies, dated October 13, 2011, by and between MabVax Therapeutics, Inc. and Sloan-Kettering Institute for Cancer Research                                                              |    | S-1/A  |    | 10/14/2014 |    | 10.29 |
|   |         |                                                                                                                                                                                                                          |         |   |
| 10.25  |    | Option Agreement, dated August 29, 2014, by and between MabVax Therapeutics, Inc. and Juno Therapeutics, Inc.                                                                                                                 |    | S-1/A  |    | 10/14/2014 |    | 10.30 |

----

| 10.26   |    | SBIR Contract from National Cancer Institute                                                                                                                |    | S-1/A  |    | 10/14/2014 |    | 10.34  |
|---------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|--------------|------------|--------------|--------|
|    |         |                                                                                                                                                        |         |   |
| 10.27   |    | Form of Exchange Agreement (Series A-1 Preferred Stock and Series A-1 Warrants).                                                                            |    | 8-K    |    | 3/26/2015  |    | 10.1   |
|    |         |                                                                                                                                                        |         |   |
| 10.28   |    | Form of Exchange Agreement (Series B Preferred Stock and Series B Warrants).                                                                                |    | 8-K    |    | 3/26/2015  |    | 10.2   |
|    |         |                                                                                                                                                        |         |   |
| 10.29   |    | 2008 Equity Incentive Plan                                                                                                                                  |    | 10-K   |    | 3/31/2015  |    | 10.29  |
|    |         |                                                                                                                                                        |         |   |
| 10.30   |    | Form of Option Agreement, 2008 Equity Incentive Plan                                                                                                        |    | 10-K   |    | 3/31/2015  |    | 10.30  |
|    |         |                                                                                                                                                        |         |   |
| 10.31   |    | Form of Lockup Agreement dated as of April 3, 2015                                                                                                          |    | 8-K    |    | 4/6/2015   |    | 10.3   |
|    |         |                                                                                                                                                        |         |   |         |       |         |   |
| 10.32   |    | Consulting Agreement with The Del Mar Consulting Group, Inc. and Alex Partners, LLC  dated as of April 5, 2015                                         |    | 8-K    |    | 4/6/2015   |    | 10.4   |
|    |         |                                                                                                                                                        |         |   |         |       |         |   |
| 10.33   |    | Form of Escrow Deposit Agreement dated as of April 14, 2015                                                                                                 |    | 8-K    |    | 4/15/2015  |    | 10.1   |
|    |         |                                                                                                                                                        |         |   |         |       |         |   |
| 11.1    |    | Statement of per share earnings                                                                                                                             |    | S-1    |    | 9/29/2014  |    | 11.1   |
|    |         |                                                                                                                                                        |         |   |
| 14.1    |    | Code of Ethics                                                                                                                                              |    | 10-K   |    | 3/5/2004   |    | 14.1   |
|    |         |                                                                                                                                                        |         |   |
| 21.1    |    | Subsidiaries of the Registrant                                                                                                                              |    | S-1    |    | 9/29/2014  |    | 21.1   |
|    |         |                                                                                                                                                        |         |   |
| 31.1**  |    | Certification of Principal Executive Officer required by Section 302 of the Sarbanes-Oxley Act of 2002                                                 |    |   |    |       |    |   |
|    |         |                                                                                                                                                        |         |   |
| 31.2**  |    | Certification of Principal Financial Officer required by Section 302 of the Sarbanes-Oxley Act of 2002                                                 |    |   |    |       |    |   |
|    |         |                                                                                                                                                        |         |   |
| 32.1*** |    | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |    |   |    |       |    |   |
|    |         |                                                                                                                                                        |         |   |
| 32.2*** |    | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |    |   |    |       |    |   |
|    |         |                                                                                                                                                        |         |   |
| 101**   |    | Interactive data file                                                                                                                                       |    |   |    |       |    |   |

| **  | Filed herewith     |
|-----|--------------------|
| *** | Furnished herewith |

----

|                              |   |                                  |   |
|-----------------------------------|--------|---------------------------------------|--------|
| MABVAX THERAPEUTICS HOLDINGS, INC |   |
|                              |   |                                  |
| By:                               |   | /s/ J. David Hansen                   |   |
|                              |   | J. David Hansen                       |   |
|                              |   | President and Chief Executive Officer |   |

| Signature                                             |    | Title                                                                                     |   | Date           |
|-------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------|--------|----------------|
|                                                  |         |                                                                                      |
| /s/ J. David HansenJ. David Hansen                    |    | Chairman of the Board, President and Chief Executive Officer(Principal executive officer) |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Gregory P. HansonGregory P. Hanson                |    | Chief Financial Officer(Principal financial and accounting officer)                       |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Kenneth M. CohenKenneth M. Cohen                  |    | Director                                                                                  |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Robert E. HoffmanRobert E. Hoffman                |    | Director                                                                                  |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Philip O. LivingstonPhilip O. Livingston, M.D.    |    | Director                                                                                  |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Paul V. MaierPaul V. Maier                        |    | Director                                                                                  |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Jeffrey V. RavetchJeffrey V. Ravetch, M.D., Ph.D. |    | Director                                                                                  |   | April 30, 2015 |
|                                                  |         |                                                                                      |
| /s/ Thomas C. VarvaroThomas C. Varvaro                |    | Director                                                                                  |   | April 30, 2015 |